Effects of vesnarinone on morbidity and mortality of patients with heart failure

Article Abstract:

A low dose of vesnarinone may be an effective and safe treatment for congestive heart failure. Treatment with a higher dose may cause life-threatening complications. Among 477 patients with congestive heart failure, 239 were treated with 60 milligrams (mg) of vesnarinone per day and 238 were treated with a placebo, or inactive substance. Twenty-six patients treated with vesnarinone had progressively worse heart failure or died, compared with 50 patients who received a placebo. Patients in the vesnarinone group experienced a significant improvement in their quality of life over a 12-week period. Of 87 patients with congestive heart failure who were treated with 120 mg of vesnarinone per day, 16 died and half of these deaths occurred within the first six weeks of treatment. Treatment with 120 mg of vesnarinone per day was discontinued because it was too dangerous.

Health aspects, Cardiotonic agents

---

Effect of amlodipine on morbidity and mortality in severe chronic heart failure

Article Abstract:

The calcium channel blocker amlodipine appears to be safe when used in patients with chronic heart failure. Researchers randomly assigned 1,135 patients in heart failure to take amlodipine or a placebo. Amlodipine reduced the risk of fatal and nonfatal cardiovascular events and also reduced the death rate. This difference was seen most dramatically in patients whose heart failure was caused by dilated cardiomyopathy. Amlodipine reduced the risk of death by 46% in this group. However, it appeared to have no effect in those with coronary heart disease.

Calcium channel blockers

---

Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure

Article Abstract:

A study conducted to find out whether, cardiac-resynchronization therapy is more beneficial with or without an implantable defibrillator, is presented. According to the study, when combined with an implantable defibrillator, cardiac-resynchronization therapy reduces mortality significantly.

United States, Usage, Diagnosis, Risk factors, Cardiac pacing, Implantable cardioverter-defibrillators

Similar abstracts:

• Abstracts: Cardiac morbidity and related mortality in children with HIV infection. Incidence, causes and outcomes of dilated cardiomyopathy in children
• Abstracts: Does degree of obesity influence the validity of reported energy and protein intake? Results from the SOS dietary questionnaire
• Abstracts: Market mania spurs drop in hospital inpatient Medicare costs. Advisory group urges HCFA to plug gaps in RBRVS
• Abstracts: Hospitals respond by expanding outside care. Woman cites ADA in bid for experimental treatment. Vermont leaning toward single-payer; budget target set
• Abstracts: Computerized patient record network not far off. Record keeping or record giving? Internet infuses new life into data networks

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.